0.600
+0.011
(1.92%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 0.57 - 0.60 |
| 52 week | 0.40 - 5.16 |
| Open | 0.57 |
| Vol / Avg. | 0.00/643,297.00 |
| Mkt cap | 16.56M |
| P/E | - |
| Div/yield | - |
| EPS | -1.05 |
| Shares | 27.60M |
| Beta | - |
| Inst. own | 45% |
Events
Apr 24, 2013
Tranzyme and Ocera Joint Conference Call to Discuss the Planned Merger and its Business Overview
|
More events from DailyFinance »
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -217.15% | -218.43% |
| Operating margin | -196.32% | -204.04% |
| EBITD margin | - | -201.01% |
| Return on average assets | -38.00% | -66.99% |
| Return on average equity | -104.27% | -239.54% |
| Employees | 47 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 300, 5001 South Miami Boulevard
DURHAM, NC 27703
United States - Map
+1-919-4740020 (Phone)
+1-919-4740025 (Fax)
DURHAM, NC 27703
United States - Map
+1-919-4740020 (Phone)
+1-919-4740025 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Tranzyme, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. The Company is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase-IIb trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis. The Company has initiated a second Phase-IIb trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis.
Officers and directors
| John H. Johnson | Independent Chairman of the Board | |
| Vipin K. Garg Ph.D. | President, Chief Executive Officer, Director | |
| Helmut Thomas Ph.D. | Senior Vice President - Research and Preclinical Development | |
| David S. Moore | Chief Business Officer | |
| Franck S. Rousseau M.D. | Chief Medical Officer | |
| George B. Abercrombie | Independent Director | |
| Jean-Paul Castaigne M.D. | Independent Director | |
| Anne M. VanLent | Independent Director | |
| Alex Zisson | Independent Director |